ID   MelHOrDACARB20
AC   CVCL_RQ54
SY   MelHOrDAC20; Mel-HOrDAC20
DR   cancercelllines; CVCL_RQ54
DR   Wikidata; Q54905179
RX   PubMed=22170099;
WW   Provider; RCCL; -; https://www.wass-michaelislab.org/rccl.php
CC   Problematic cell line: Misidentified/contaminated. Parent cell line (Mel-Ho) was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile.
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_4305; Dacarbazine (DTIC; (5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide)).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1402 ! Mel Ho
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 14-08-25; Version: 12
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129; PMCID=PMC3252738;
RA   Michaelis, Martin
RA   Rothweiler, Florian
RA   Barth, Susanne
RA   Cinatl, Jaroslaw
RA   van Rikxoort, Marijke
RA   Loschmann, Nadine
RA   Voges, Yvonne
RA   Breitling, Rainer
RA   von Deimling, Andreas
RA   Rodel, Franz
RA   Weber, Kristoffer
RA   Fehse, Boris
RA   Mack, Elisabeth
RA   Stiewe, Thorsten
RA   Doerr, Hans-Wilhelm
RA   Speidel, Daniel
RA   Cinatl, Jindrich Jr.
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//